Given that afatinib suppresses the activation of pan-ErbB family with high potency [34], the VEGF-driven pathobiology may be partly alleviated in tumor microenvironment and, thus, reduced the additional efficacy of VEGF-targeting agents. This evidence concerns the gene EGFR and neoplasm.